103500-22-7

Usage

Uses

Used in Pharmaceutical Industry:
Benzyl 1-(hydroxymethyl)cyclopropylcarbamate is used as a pharmaceutical intermediate for the synthesis of various medicinally important compounds. Its unique structure allows it to be a key component in the development of new drugs, contributing to the advancement of medical treatments.
Used in Organic Chemistry:
In the field of organic chemistry, benzyl 1-(hydroxymethyl)cyclopropylcarbamate is used as a building block for the preparation of other carbamate derivatives and cyclopropyl-containing compounds. Its chemical and physical properties make it a valuable asset in the synthesis of diverse chemical compounds with potential biological and pharmaceutical applications. This versatility in synthesis can lead to the discovery of new compounds with novel properties and uses.

Upstream product

• 84677-06-5 (benzyloxycarbonylamino)cyclopropanecarboxylic acid 
• 501-53-1 benzyl chloroformate 
• 85452-41-1 ethyl 1-<(benzyloxycarbonyl)amino>cyclopropanecarboxylate 

Downstream Products

• 441786-55-6 benzyl 1-({[t-butyl(diphenyl)silyl]oxy}methyl)cyclopropylcarbamate 
• 1245794-14-2 (1-(((4-chloro-6-methoxyquinolin-7-yl)oxy)methyl)cyclopropyl)carbamic acid benzyl ester 
• 1245794-02-8 1-[(4-acetyl-2-methoxyphenoxy)methyl]-N-benzyloxycarbonyl-1-aminocyclopropane 
• 441784-97-0 benzyl 1-{[t-butyl(diphenylsilyl)oxy]methylcyclopropyl}(methyl)carbamate 
• 1199792-80-7 benzyl (1-{[(tert-butyloxycarbonyl)amino]methyl}cyclopropyl)carbamate 
• 1199792-79-4 benzyl [1-(azidomethyl)cyclopropyl]carbamate 
• 1058137-81-7 1-(benzyloxycarbonylamino)cyclopropylmethyl methanesulfonate 
• 103500-24-9 ethyl (E)-3-<1-<(benzyloxycarbonyl)amino>cyclopropyl>-2-propenoate 
• 103500-23-8 1-<(benzyloxycarbonyl)amino>cyclopropanecarboxaldehyde 
• 1616278-12-6 C₁₈H₂₆N₂O₄ 
• 1616278-11-5 C₁₃H₁₈N₂O₂*C₂HF₃O₂ 
• 1616278-09-1 C₁₇H₂₆N₂O₃S 
• 1374973-41-7 C₁₆H₂₂N₂O₃S 
• 1616278-07-9 C₁₈H₂₆N₂O₄ 

Relevant academic research and scientific papers

NUCLEOSIDE PHOSPHONATE DERIVATIVES USEFUL IN THE TREATMENT OF HIV INFECTIONS

The present invention relates to a method of treating HIV infections by administering a nucleoside phosphonate derivative represented by formula (I).

Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors

Aminoguanidine and alkoxyguanidine compounds are described, including compounds of the Formula VII: wherein X is O or NR9and Het, R1, R7, R8, R12-R15, Ra, Rb, Rc, Z, and n are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing such compounds. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

Inactivation of γ-Aminobutyric Acid Aminotransferase by (S,E)-4-Amino-5-fluoropent-2-enoic Acid and Effect on the Enzyme of (E)-3-(1-Aminocyclopropyl)-2-propenoic Acid

(S,E)-4-Amino-5-fluoropent-2-enoic acid (6) is synthesized in six steps starting from the known γ-aminobutyric acid aminotransferase (γ-Abu-T) inactivator, (S)-4-amino-5-fluoropentanoic acid (1).Compound 6 is a mechanism-based inactivator of γ-Abu-T: time-dependent inactivation is saturable and protected by substrate; thiols do not protect the enzyme from inactivation; no enzyme activity returns upon dialysis.This compound (6) binds 50 times more tightly to γ-Abu-T than does the saturated analogue (1).No transamination of 6 occurs prior to inactivation.However, five molecules of 6 are required to inactivate the enzyme with concomitant release of five fluoride ions.Therefore, four molecules are being converted to product for each inactivation event. (E)-3-(1-Aminocyclopropyl)-2-propenoic acid is synthesized in seven steps from 1-aminocyclopropanecarboxylic acid.It is prepared as a cyclopropyl derivative of the proposed intermediate in the inactivation of γ-Abu-T by 6.The cyclopropyl derivative, however, is a noncompetitive inhibitor and does not inactivate the enzyme.This study shows the usefulness and hazards of incorporation of a trans double bond into potential γ-Abu-T inactivators.